Methylnaltrexone: Phase I data

In Phase I trials in 61 healthy volunteers, 2 different formulations of oral MNTX were well tolerated and had predictable pharmacokinetics. Subcutaneous MNTX is in 2 Phase III trials for opioid-induce...